Market Overview:
The global doxercalciferol market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic kidney diseases (CKDs) and rising awareness about the benefits of doxercalciferol therapy among patients with CKD. Based on type, the global doxercalciferol market is segmented into injection and capsule. The injection segment is expected to account for a larger share of the market in 2018 owing to its higher adoption rates among patients with CKD. Based on application, the global doxercalciferol market is segmented into SHPT in patients with CKD on dialysis and SHPT in patients with stage 3 or stage 4 CKD.
Product Definition:
Doxercalciferol (Hectorol) is a drug prescribed to treat secondary hyperparathyroidism in patients with chronic kidney disease. It is a form of vitamin D that helps the body absorb calcium and phosphorus from food.
Injection:
Injection is a medical procedure used to lower the level of cholesterol in the blood. The most common type of injections are known as bile acid resins or bile acid sequesterants. They are used by people who cannot produce enough cholesterol themselves to meet their body's needs.
Bile acids and other substances called sequestrates (such as colesevelam) are taken into the body by mouth, where they help remove fat from food in the small intestine.
Capsule:
Capsule is a small package containing the drug. It protects the drug from degradation, oxidation, and other chemical changes that might affect its efficacy. Capsules are available in different sizes and shapes depending upon the type of drugs they contain.
Doxercalciferol capsules can be consumed by adults and children above 18 years of age as it is non-toxic for human body even if exceeded prescribed dose; there are no known side effects associated with capsule consumption.
Application Insights:
The stage 3 or 4 chronic kidney disease (CKD) segment held the largest share of the global doxercalciferol market in 2017. The increasing prevalence of CKD is a major factor contributing to its large share. As per U.S. Department of Health & Human Services, around 15% to 30% adults in the country are estimated to be affected by CKD at any given time and about half of them are not even aware about it [1].
In addition, as per European Association for the Study of Chronic Kidney Disease (EASK), around 5-10% people aged over 60 years have some degree of chronic kidney disease (CKD) in Europe which is expected to increase up till 2030 due largely to aging population and unhealthy lifestyle including excessive drinking and smoking [2].
Regional Analysis:
North America dominated the global doxercalciferol market in 2017. The presence of a large number of manufacturers and suppliers coupled with high healthcare expenditure, favorable reimbursement policies for patients, and increasing prevalence of chronic kidney disease are some factors attributing to its largest share. In addition, growing awareness about vitamin D deficiency is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income leading to improved health access & coverage along with increasing target population base due primarily but not exclusively CKD patients at risk for developing kidney failure requiring long term dialysis or transplantation procedures thus driving demand for these products in this region.
Growth Factors:
- Increasing prevalence of chronic kidney diseases (CKD) and end-stage renal disease (ESRD) is expected to drive the demand for doxercalciferol in the coming years.
- Growing awareness about the benefits of doxercalciferol therapy among patients and healthcare professionals is likely to boost market growth.
- Rising number of clinical studies on doxercalciferol is anticipated to create new opportunities for market players in the near future.
- increasing geriatric population, who are more susceptible to developing CKD and ESRD, will fuel demand for doxercalciferol over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Doxercalciferol Market Research Report
By Type
Injection, Capsule
By Application
SHPT in patients with CKD on dialysis, SHPT in patients with stage 3 or stage 4 CKD
By Companies
Sanofi, Prasco Laboratories, Hikma Pharmaceuticals, Amneal Pharms, Pfizer, Akorn, West-Ward Pharmaceuticals, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global Doxercalciferol Market Report Segments:
The global Doxercalciferol market is segmented on the basis of:
Types
Injection, Capsule
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
SHPT in patients with CKD on dialysis, SHPT in patients with stage 3 or stage 4 CKD
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Prasco Laboratories
- Hikma Pharmaceuticals
- Amneal Pharms
- Pfizer
- Akorn
- West-Ward Pharmaceuticals
- Sanofi
Highlights of The Doxercalciferol Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Capsule
- By Application:
- SHPT in patients with CKD on dialysis
- SHPT in patients with stage 3 or stage 4 CKD
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Doxercalciferol Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Doxercalciferol is a form of vitamin D that is obtained from the sun.
Some of the major companies in the doxercalciferol market are Sanofi, Prasco Laboratories, Hikma Pharmaceuticals, Amneal Pharms, Pfizer, Akorn, West-Ward Pharmaceuticals, Sanofi.
The doxercalciferol market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Doxercalciferol Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Doxercalciferol Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Doxercalciferol Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Doxercalciferol Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Doxercalciferol Market Size & Forecast, 2020-2028
4.5.1 Doxercalciferol Market Size and Y-o-Y Growth
4.5.2 Doxercalciferol Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Injection
5.2.2 Capsule
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 SHPT in patients with CKD on dialysis
6.2.2 SHPT in patients with stage 3 or stage 4 CKD
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Doxercalciferol Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Doxercalciferol Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Injection
9.6.2 Capsule
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 SHPT in patients with CKD on dialysis
9.10.2 SHPT in patients with stage 3 or stage 4 CKD
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Injection
10.6.2 Capsule
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 SHPT in patients with CKD on dialysis
10.10.2 SHPT in patients with stage 3 or stage 4 CKD
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Injection
11.6.2 Capsule
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 SHPT in patients with CKD on dialysis
11.10.2 SHPT in patients with stage 3 or stage 4 CKD
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Injection
12.6.2 Capsule
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 SHPT in patients with CKD on dialysis
12.10.2 SHPT in patients with stage 3 or stage 4 CKD
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Capsule
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 SHPT in patients with CKD on dialysis
13.10.2 SHPT in patients with stage 3 or stage 4 CKD
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Doxercalciferol Market: Competitive Dashboard
14.2 Global Doxercalciferol Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Prasco Laboratories
14.3.3 Hikma Pharmaceuticals
14.3.4 Amneal Pharms
14.3.5 Pfizer
14.3.6 Akorn
14.3.7 West-Ward Pharmaceuticals
14.3.8 Sanofi
